Skip to content
The Policy VaultThe Policy Vault

XyremBlue Cross Blue Shield of Oklahoma

narcolepsy with excessive daytime sleepiness

Preferred products

  • Authorized generic Sodium Oxybate

Initial criteria

  • If request for brand Xyrem, ONE of the following:
  • Patient currently stable on requested agent OR
  • Tried authorized generic Sodium Oxybate with inadequate response or discontinued due to adverse event/intolerance/contraindication OR
  • Authorized generic Sodium Oxybate expected ineffective, not in best interest, worsens comorbid condition, causes barriers, or harm OR
  • Patient has tried another drug in same pharmacologic class/mechanism as authorized generic Sodium Oxybate and discontinued due to ineffectiveness or side effects OR
  • There is support for use over authorized generic Sodium Oxybate
  • Prescriber must be specialist or consult specialist
  • No FDA labeled contraindications

Reauthorization criteria

  • 1. Patient previously approved for Xyrem through plan PA process AND
  • 2. Prescriber is or consulted with relevant specialist AND
  • 3. Patient shows clinical benefit AND
  • 4. No contraindications

Approval duration

12 months